Most surprisingly, treatment with the combination of the two drugs was the most effective strategy in this obesity model, significantly reducing BW and improving several plasma biochemical parameters (triglycerides, LDL, ALT, and AST), suggesting that the simultaneous targeting of PPARα, CB1, and GLP-1R receptors may be the key for effective obesity treatment. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.